Cancer

HDAC6, a cytoplasmic deacetylase best known for shaping cell stress responses, is emerging as an unusually informative flag in blood...

A new study from researchers in 2026 reports that tumor progression can disrupt ovarian function even when tumors are not...

In leukemia’s most aggressive settings, bone marrow–resident blood-cell factories fail to complete normal maturation. Instead of rapidly generating mature immune...

Tumour biopsy remains the clinical gold standard for diagnosing cancer and guiding biomarker-based treatment choices. By interrogating the tumour itself,...

Pancreatic cancer is notoriously resistant to immunotherapy because many tumors develop an immune-suppressive, oxygen-poor “cold” microenvironment that blocks effective T...

A new analysis from a large, single-centre cohort suggests that when immune checkpoint inhibitors are given can meaningfully shape outcomes...

A new randomized Phase II clinical trial, OPTIM, is testing whether escalating immune therapy can improve outcomes for people with...

Advanced colorectal cancer remains one of oncology’s toughest challenges, especially in pathological T4 (pT4) disease where outcomes are often grim....

A simple blood test may soon help clinicians manage metastatic castration-resistant prostate cancer (mCRPC) more precisely, according to a study...

Pancreatic cancer remains among the deadliest malignancies, in part because tumors often withstand chemotherapy and later acquire resistance. In recent...